Altimmune Inc - ALT Net earnings per share (EPS TTM)

Altimmune, Inc. (ALT) develops advanced peptide therapies to combat obesity and liver pathologies. Pemvidutide holds particular potential by minimizing muscle loss, which enhances the company's capitalization. This price chart reflects the EPS (TTM) dynamics, which currently stand at 32.20. However, the success of the entire biotech sector depends on regulatory approval, as commercial sales have not yet been launched.

Altimmune Corp (ALT) - Earnings per share for the last twelve months from 02/11/2024 to 11/15/2026

altimmune.com - analytical breakdowns and key metrics (ALT)

- stock price and consensus target price:

Price Altimmune|ALT - Analyst Consensus Forecast

- issuer market value details:

Market Capitalization Altimmune Corp|ALT - Enterprise Value

- shareholders' equity book value data:

Net Assets per Single Share Altimmune|ALT - Company Book Value|Market-to-Book Ratio altimmune.com|ALT - Aggregate Company Assets

- company total debt and liquidity indicators:

- earnings and valuation multiples indicators:

ALT - Company Net Income|Expected Profit Altimmune, Inc.|ALT - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Altimmune Corp|ALT - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Altimmune Pharma|ALT - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Altimmune|ALT - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months altimmune.com|ALT - Net earnings per share growth this year|Earnings growth forecast for next year Altimmune, Inc.

- revenue and sales details:

ALT - Company Revenue|Company Revenue Forecast Altimmune|ALT - P/S Multiple|Market Cap to Future Revenue Ratio Altimmune|ALT - Revenue Growth YoY (Last 12 Months)

Initial company analysis:ALT (Altimmune Inc)

Conservative capital demands absolute profit transparency to confirm the sustainability of the business model. This indicator measures the annual change in net income per share over the last 12 months, revealing the actual efficiency of cost and revenue management. For Altimmune, Inc. (ALT), this is a critical marker of the transition from the costly development of Pemvidutide to monetization within the obesity segment. By analyzing the EPS YoY TTM trend, investors assess the company's readiness to scale within the metabolic therapy market.

Competitor analysis